OPTCEUTICS LIMITED
Company number 10015972 · Monitor this company
The confirmation statement for this company is overdue.
Executive summary
Optceutics Limited presents a HIGH risk investment case. The company is in liquidation with deeply negative net assets of £80,874, shareholders' funds of minus £403,327, and virtually no cash (£292). The dramatic deterioration from a marginally positive net asset position in 2023 to severe insolvency in 2024, combined with a seven-fold increase in other creditors and an overdue confirmation statement, indicates financial distress has overwhelmed the business. Any residual value depends on the realisation of intellectual property related to the PK-Eye technology, and the position of creditors and shareholders will be determined by the liquidation process.
Shareholders' funds
-£403,327
Balance sheet as at 2024-03-31
Overview
- Company type
- Private Limited Company
- Incorporated
- 2016-02-19
- Registered office
- 26 Stroudley Road, Brighton, East Sussex, BN1 4BH
- Postcode
- BN1 4BH
- Capital
- 1 USD
- Accounts category
- Total Exemption Full
Accounts
- Last made up to
- 2024-03-31
- Next due by
- 2026-06-30
- Financial year end
- 30 September
Confirmation statement
- Last statement dated
- 2025-02-18
- Next due by
- 2026-03-04 Overdue
Nature of business (SIC)
- 72110 Research and experimental development on biotechnology
Officers 3 current · 1 resigned
Contact details
- Website
- optceutics.com
Optceutics Ltd has developed the PK-Eye a unique high throughout pharmacokinetic model. Mimicing drug clearance from the human eye, the PK-Eye can be used to accelerate and streamline the development, formulation and regulatory approval of novel, generic, or biosimilar drugs for intra-ocular use.
The class of 2016
36%
of the 402 companies in this sector incorporated in 2016 are still active today; 59% have since been dissolved.
A fact about the year, not a forecast for this company.